LGC acquires antigens and antibodies company NAC

By LabPulse.com staff writers

July 9, 2020 -- Life sciences company LGC has acquired the Native Antigen Company (NAC), an Oxford, U.K.-based supplier of infectious disease antigens and antibodies.

NAC's portfolio includes 60 viral and infectious disease products, including pathogen receptors, virus-like particles and antibodies for immunoassay technologies, and vaccine development and quality control solutions. The global supplier also offers antigens for SARS-CoV-2 to help researchers respond to the COVID-19 pandemic.

The acquisition will bolster LGC's product offerings in the IVD market, according to the company. LGC's existing IVD offerings include quality assurance tools, immunoassay reagents, disease-state plasma, and probes and primers for molecular diagnostics.


Copyright © 2020 LabPulse.com
 

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?